{"schema_version":"secwatch.filing_event.v1","accession":"0001830214-25-000013","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.681045+00:00","generated_at":"2026-05-16T23:57:59.981753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ginkgo Q3 revenue $39M (-56% YoY); net loss $81M; reaffirms FY guide $167-187M","bullets":["Total revenue $39M, down 56% YoY; prior year had $45M non-cash deferred revenue; ex that, down 11%.","GAAP net loss $81M vs $56M prior; Adjusted EBITDA loss $56M vs $20M.","Reaffirms FY25 revenue $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M.","Cash & securities $462M; expands autonomous lab; Bayer partnership extended, BARDA contract up to $22.2M.","Cell Engineering revenue $29M (-61% YoY); Biosecurity $9M ($14M prior)."],"urls":{"canonical":"https://secwatch.observer/filing/0001830214-25-000013","json":"https://secwatch.observer/filing/0001830214-25-000013.json","markdown":"https://secwatch.observer/filing/0001830214-25-000013.md","text":"https://secwatch.observer/filing/0001830214-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000183021425000013/0001830214-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000183021425000013/dna-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:57:59.981753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}